[Study of the pharmacokinetics of extended release sildenafil].

Q4 Medicine Urologiia Pub Date : 2024-09-01
B Kurta I, V Zakharova A, F Guranda D, I Kuzmin A, V Isakov F, I Shaburov R, G Belolipetskaya V
{"title":"[Study of the pharmacokinetics of extended release sildenafil].","authors":"B Kurta I, V Zakharova A, F Guranda D, I Kuzmin A, V Isakov F, I Shaburov R, G Belolipetskaya V","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of the study: </strong>Comparison of the pharmacokinetic characteristics of the drug Vildegra registered in the Russian Federation with literature data for the original drug Viagra.</p><p><strong>Materials and methods: </strong>Study design: prospective, open-label in healthy volunteers with a single oral dose on an empty stomach. The study included 48 male volunteers aged 18 to 45 years with a verified diagnosis of \"healthy.\" All subjects of the clinical study took 1 tablet of Vildegra once on an empty stomach. Blood samples to determine the concentrations of active substances were taken before taking the study drug and then after 0.25; 0.5; 0.75; 1; 1.5; 2; 2.5; 3; 3.5; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 16; 24; thirty; 36; 48 and 72 hours after taking the drug. Dynamic monitoring was carried out throughout the study, including clinical examination, measurement of vital signs, monitoring of laboratory parameters and monitoring of adverse events (AE). The concentrations of sildenafil and its active metabolite N-desmethylsildenafil in the blood plasma of volunteers were determined by high-performance liquid chromatography with tandem mass spectrometric detection. Pharmacokinetic parameters were calculated using a model-free method using the specialized program PK Solution2.0.</p><p><strong>Results: </strong>The AUC0-t, AUC0- and Cmax values for sildenafil and its active metabolite when taking the drug Vildegra are in good agreement with the literature data for the original drug Viagra. The values of tmax and t1/2 of the drug Vildegra are slightly higher than those of the original drug, which is apparently explained by the extended-release dosage form in the case of Vildegra. In 10 of 48 volunteers (21%), 20 AE were recorded, which resulted in complete recovery. No serious or unexpected AE were noted.</p><p><strong>Conclusion: </strong>The results obtained allow us to conclude that the pharmacokinetics, good tolerability and satisfactory safety profile of the drug Vildegra are comparable with the published data for the original drug Viagra.</p>","PeriodicalId":23546,"journal":{"name":"Urologiia","volume":" 4","pages":"22-28"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of the study: Comparison of the pharmacokinetic characteristics of the drug Vildegra registered in the Russian Federation with literature data for the original drug Viagra.

Materials and methods: Study design: prospective, open-label in healthy volunteers with a single oral dose on an empty stomach. The study included 48 male volunteers aged 18 to 45 years with a verified diagnosis of "healthy." All subjects of the clinical study took 1 tablet of Vildegra once on an empty stomach. Blood samples to determine the concentrations of active substances were taken before taking the study drug and then after 0.25; 0.5; 0.75; 1; 1.5; 2; 2.5; 3; 3.5; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 16; 24; thirty; 36; 48 and 72 hours after taking the drug. Dynamic monitoring was carried out throughout the study, including clinical examination, measurement of vital signs, monitoring of laboratory parameters and monitoring of adverse events (AE). The concentrations of sildenafil and its active metabolite N-desmethylsildenafil in the blood plasma of volunteers were determined by high-performance liquid chromatography with tandem mass spectrometric detection. Pharmacokinetic parameters were calculated using a model-free method using the specialized program PK Solution2.0.

Results: The AUC0-t, AUC0- and Cmax values for sildenafil and its active metabolite when taking the drug Vildegra are in good agreement with the literature data for the original drug Viagra. The values of tmax and t1/2 of the drug Vildegra are slightly higher than those of the original drug, which is apparently explained by the extended-release dosage form in the case of Vildegra. In 10 of 48 volunteers (21%), 20 AE were recorded, which resulted in complete recovery. No serious or unexpected AE were noted.

Conclusion: The results obtained allow us to conclude that the pharmacokinetics, good tolerability and satisfactory safety profile of the drug Vildegra are comparable with the published data for the original drug Viagra.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[缓释西地那非的药代动力学研究]。
研究目的比较在俄罗斯联邦注册的药物 Vildegra 的药代动力学特征与原研药万艾可的文献数据:研究设计:前瞻性、开放标签,健康志愿者空腹口服一次。研究对象包括 48 名年龄在 18 至 45 岁之间、经核实诊断为 "健康 "的男性志愿者。所有临床研究对象空腹一次服用 1 片 Vildegra。在服用研究药物前,以及服药后 0.25、0.5、0.75、1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、7、8、10、12、16、24、30、36、48 和 72 小时后,分别采集血液样本以测定活性物质的浓度。在整个研究过程中进行动态监测,包括临床检查、生命体征测量、实验室参数监测和不良事件(AE)监测。志愿者血浆中西地那非及其活性代谢物 N-去甲基西地那非的浓度是通过高效液相色谱法和串联质谱检测法测定的。药代动力学参数的计算采用无模型法,使用专用程序 PK Solution2.0.Results:服用 Vildegra 药物时,西地那非及其活性代谢物的 AUC0-t、AUC0- 和 Cmax 值与原研药万艾可的文献数据十分吻合。Vildegra 药物的 tmax 和 t1/2 值略高于原研药,这显然是由于 Vildegra 采用了缓释剂型。在 48 名志愿者中,有 10 人(21%)出现了 20 次不良反应,但均已完全恢复。没有发现严重或意外的不良反应:根据所获得的结果,我们可以得出结论,Vildegra 药物的药代动力学、良好的耐受性和令人满意的安全性与已公布的原研药万艾可的数据相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urologiia
Urologiia Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
160
期刊最新文献
[Experience in managing children with foreign bodies in the lower urinary tract]. [Features of histo- and angioarchitectonics of the prostate during the progression of bph and the development of its complications]. [First results of using the original urethral speculum for diagnosing chronic skenitis]. [How to help a patient with abacterial prostatitis?] [Modern optical non-invasive technologies in diagnostics of urological diseases. Literature review. Part I].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1